[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.147.238.168. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
March 2001

Intravitreal Injection of Tissue Plasminogen Activator: Four Considerations

Arch Ophthalmol. 2001;119(3):456-457. doi:

In reply

We appreciate the thoughtful comments of Dr Hesse regarding adverse effects of intravitreal commercial tPA solution on the retina. It is reasonable to assume that the larger volume of the human vitreous should raise the threshold for tPA toxicity compared with the cat eye. However, we have shown that the larger volume of the cat vitreous cavity compared with that of the rabbit does not increase the margin of safety for intravitreal tPA.1,2 This fact, together with the geographic distribution of toxic changes around the injection site, suggests that tPA is not diluted evenly throughout the vitreous cavity. Extrapolations of safe doses based on vitreous volume may therefore be inaccurate.

First Page Preview View Large
First page PDF preview
First page PDF preview
×